{"id":2277,"date":"2025-12-17T18:22:08","date_gmt":"2025-12-17T15:22:08","guid":{"rendered":"https:\/\/demetdemircioglu.com\/?p=2277"},"modified":"2025-12-17T18:35:40","modified_gmt":"2025-12-17T15:35:40","slug":"fibromiyalji-tedavisi","status":"publish","type":"post","link":"https:\/\/demetdemircioglu.com\/en\/fibromiyalji-tedavisi\/","title":{"rendered":"Fibromiyalji Tedavisi"},"content":{"rendered":"\n<p class=\"gtfy-1\"><strong>Fibromiyalji Tedavisinde Yeni Ufuklar: Tonmya\u2019n\u0131n FDA Onay\u0131 ve G\u00fcncel Tedavi Geli\u015fmeleri (2024\u20132025)<\/strong><\/p>\n\n\n\n<p class=\"gtfy-4\"><strong>\u00d6zet<\/strong><\/p>\n\n\n\n<p class=\"gtfy-7\"><strong>Ama\u00e7:<\/strong>&nbsp;Bu derleme, 2024\u20132025 y\u0131llar\u0131nda fibromiyalji (FM) alan\u0131nda kaydedilen g\u00fcncel tedavi geli\u015fmelerini, \u00f6zellikle Tonmya&#8217;n\u0131n (cyclobenzaprine hydrochloride sublingual) ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA) taraf\u0131ndan onaylanmas\u0131n\u0131 merkeze alarak de\u011ferlendirmeyi ama\u00e7lamaktad\u0131r.<\/p>\n\n\n\n<p class=\"gtfy-10\"><strong>Y\u00f6ntem:<\/strong>&nbsp;Son bir y\u0131l i\u00e7inde yay\u0131mlanan randomize kontroll\u00fc \u00e7al\u0131\u015fmalar, meta-analizler ve g\u00fcncel klinik k\u0131lavuzlar incelenmi\u015ftir.<\/p>\n\n\n\n<p class=\"gtfy-13\"><strong>Bulgular:<\/strong>&nbsp;Tonmya, 15 y\u0131ldan uzun s\u00fcredir FDA onay\u0131 alan ilk FM ilac\u0131 olup, d\u00fc\u015f\u00fck doz gece uygulanabilen dilalt\u0131 form\u00fclasyonuyla uyku bozuklu\u011funu hedeflemektedir. Ayr\u0131ca dijital davran\u0131\u015f terapileri, n\u00f6romod\u00fclasyon teknikleri, ba\u011f\u0131rsak mikrobiyotas\u0131yla ili\u015fkili mekanistik bulgular ve diyet m\u00fcdahaleleri gibi \u00e7ok say\u0131da yakla\u015f\u0131m, hastal\u0131\u011f\u0131n y\u00f6netiminde multidisipliner bir anlay\u0131\u015f\u0131 desteklemektedir.<\/p>\n\n\n\n<p class=\"gtfy-16\"><strong>Sonu\u00e7:<\/strong>&nbsp;Tonmya\u2019n\u0131n onay\u0131 ve paralel geli\u015fmeler, FM tedavisinde yeni bir d\u00f6nemin ba\u015flang\u0131c\u0131 olabilir. Ancak, uzun d\u00f6nem ger\u00e7ek ya\u015fam verileri ve damgalama kaynakl\u0131 eri\u015fim sorunlar\u0131 dikkate al\u0131nmal\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"gtfy-19\"><strong>Anahtar kelimeler:<\/strong>&nbsp;Fibromiyalji, Tonmya, cyclobenzaprine, dijital terapi, n\u00f6romod\u00fclasyon, mikrobiyota<\/p>\n\n\n\n<p class=\"gtfy-22\"><strong>Giri\u015f<\/strong><\/p>\n\n\n\n<p class=\"gtfy-25\">Fibromiyalji (FM), etiyolojisi tam olarak a\u00e7\u0131klanamam\u0131\u015f, yayg\u0131n kas-iskelet sistemi a\u011fr\u0131s\u0131, yorgunluk, uyku bozuklu\u011fu, bili\u015fsel i\u015flev bozuklu\u011fu (\u201cfibro fog\u201d) ve depresif belirtiler ile karakterize kronik bir sendromdur. Epidemiyolojik \u00e7al\u0131\u015fmalara g\u00f6re d\u00fcnya n\u00fcfusunun %2\u20134\u2019\u00fcn\u00fc etkilemekte olup kad\u0131nlarda daha s\u0131k g\u00f6r\u00fclmektedir [1].<\/p>\n\n\n\n<p class=\"gtfy-28\">FM\u2019nin tan\u0131 ve tedavisinde y\u0131llard\u0131r s\u00fcregelen tart\u0131\u015fmalar\u0131n temelinde biyobelirte\u00e7 eksikli\u011fi, heterojen semptom profili ve t\u0131bbi damgalama sorunu yer almaktad\u0131r. FM\u2019ye y\u00f6nelik en son FDA onay\u0131 2009 y\u0131l\u0131nda ger\u00e7ekle\u015fmi\u015f olup bu tarihten sonra yeni farmakolojik tedavi onaylanmam\u0131\u015ft\u0131r. Ancak 2025 y\u0131l\u0131nda Tonmya adl\u0131 yeni bir ila\u00e7 bu gidi\u015fat\u0131 de\u011fi\u015ftirmi\u015ftir [2].<\/p>\n\n\n\n<p class=\"gtfy-31\">Bu derleme, 2024\u20132025 d\u00f6neminde FM tedavisine y\u00f6nelik \u00f6nemli geli\u015fmeleri bilimsel d\u00fczlemde de\u011ferlendirmektedir.<\/p>\n\n\n\n<p class=\"gtfy-34\"><strong>Tonmya (Cyclobenzaprine HCl SL): Yeni Farmakolojik Yakla\u015f\u0131m<\/strong><\/p>\n\n\n\n<p class=\"gtfy-37\"><strong>\u0130lac\u0131n \u00d6zellikleri<\/strong><\/p>\n\n\n\n<p class=\"gtfy-40\">Tonmya (cyclobenzaprine HCl sublingual), klasik siklobenzaprine&#8217;in oral form\u00fclasyonundan farkl\u0131 olarak, d\u00fc\u015f\u00fck doz ve gece uygulanan dilalt\u0131 bir formdur. Kas gev\u015fetici olarak bilinen bu molek\u00fcl, fibromiyaljide uyku mimarisi bozulmalar\u0131n\u0131 hedefleyerek yava\u015f dalga uykuyu desteklemekte, ini\u015f y\u00f6nl\u00fc a\u011fr\u0131 mod\u00fclasyonunu art\u0131rmakta ve merkezi sensitizasyonu azaltmay\u0131 ama\u00e7lamaktad\u0131r [3].<\/p>\n\n\n\n<p class=\"gtfy-43\"><strong>Klinik Kan\u0131tlar<\/strong><\/p>\n\n\n\n<p class=\"gtfy-46\">Tonmya&#8217;n\u0131n FDA onay\u0131 \u00fc\u00e7 ana Faz 3 \u00e7al\u0131\u015fmaya dayanmaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list gtfy-52\">\n<li class=\"gtfy-49 gutenify-list-item\"><strong>RELIEF \u00c7al\u0131\u015fmas\u0131 (n=503):<\/strong>\u00a0Plasebo kontroll\u00fc, \u00e7ift k\u00f6r. A\u011fr\u0131 \u015fiddeti, uyku kalitesi ve PGIC skorlar\u0131nda anlaml\u0131 iyile\u015fme sa\u011fland\u0131 [4].<\/li>\n\n\n\n<li class=\"gtfy-50 gutenify-list-item\"><strong>AFFIRM \u00c7al\u0131\u015fmas\u0131 (n=383):<\/strong>\u00a0\u0130\u015flevsel iyile\u015fmeyi \u00f6nceliklendiren Faz 3 \u00e7al\u0131\u015fmada Tonmya, plaseboya \u00fcst\u00fcn bulundu.<\/li>\n\n\n\n<li class=\"gtfy-51 gutenify-list-item\"><strong>FLEX Uzun D\u00f6nem G\u00fcvenlik \u00c7al\u0131\u015fmas\u0131 (n=470):<\/strong>\u00a012 ay boyunca ilac\u0131n g\u00fcvenli\u011fi ve tolere edilebilirli\u011fi izlendi. Yayg\u0131n yan etkiler aras\u0131nda ba\u015f a\u011fr\u0131s\u0131, a\u011f\u0131z kurulu\u011fu ve uyku s\u0131ras\u0131nda al\u0131\u015f\u0131lmad\u0131k r\u00fcyalar yer ald\u0131. Sedasyon oran\u0131 oral forma g\u00f6re anlaml\u0131 olarak daha d\u00fc\u015f\u00fckt\u00fc [5].<\/li>\n<\/ul>\n\n\n\n<p class=\"gtfy-55\"><strong>Klinik De\u011ferlendirme<\/strong><\/p>\n\n\n\n<p class=\"gtfy-58\">Tonmya, \u00f6zellikle uyku bozuklu\u011fu bask\u0131n ve polifarmasi riski ta\u015f\u0131yan hastalarda potansiyel bir se\u00e7enek sunmaktad\u0131r. Ancak, ger\u00e7ek ya\u015fam verilerinin yetersizli\u011fi ve farkl\u0131 hasta alt gruplar\u0131ndaki etkilili\u011fi hen\u00fcz net de\u011fildir.<\/p>\n\n\n\n<p class=\"gtfy-61\"><strong>Di\u011fer Geli\u015fmeler: Dijital Terapiler ve Alternatif Yakla\u015f\u0131mlar<\/strong><\/p>\n\n\n\n<p class=\"gtfy-64\"><strong>FM-ACT Mobil Uygulamas\u0131<\/strong><\/p>\n\n\n\n<p class=\"gtfy-67\">PROSPER-FM adl\u0131 randomize kontroll\u00fc \u00e7al\u0131\u015fmada (n=275), Acceptance and Commitment Therapy (ACT) temelli mobil uygulaman\u0131n semptom \u015fiddetini azaltmada etkili oldu\u011fu g\u00f6sterilmi\u015ftir. Bu y\u00f6ntem, \u00f6zellikle ila\u00e7 kullanmak istemeyen ya da eri\u015fim sorunu ya\u015fayan hastalar i\u00e7in \u00f6nemlidir [6].<\/p>\n\n\n\n<p class=\"gtfy-70\"><strong>N\u00f6romod\u00fclasyon Teknikleri<\/strong><\/p>\n\n\n\n<p class=\"gtfy-73\">Son y\u0131llarda vagus siniri uyar\u0131m\u0131 (nVNS), transkraniyal manyetik stim\u00fclasyon (rTMS) ve limbik n\u00f6rogeribildirim y\u00f6ntemleri, merkezi a\u011fr\u0131 i\u015fleme bozukluklar\u0131n\u0131 hedefleyen tamamlay\u0131c\u0131 stratejiler olarak \u00e7al\u0131\u015f\u0131lmaktad\u0131r [7]. Bu teknikler genellikle k\u00fc\u00e7\u00fck \u00f6rneklemli pilot \u00e7al\u0131\u015fmalara dayansa da, semptom skorlar\u0131nda anlaml\u0131 azalmalar bildirilmi\u015ftir.<\/p>\n\n\n\n<p class=\"gtfy-76\"><strong>Mikrobiyota ve Metabolit Ara\u015ft\u0131rmalar\u0131<\/strong><\/p>\n\n\n\n<p class=\"gtfy-79\">Mendelian randomizasyon analizleri, belirli ba\u011f\u0131rsak mikrobiyota t\u00fcrleri ve plazma metabolitleri ile fibromiyalji riski aras\u0131nda nedensel ili\u015fki oldu\u011funu ortaya koymu\u015ftur. Omega-3, GLP-1 ve kafein metabolizmas\u0131 yollar\u0131 \u00fczerinde durulmaktad\u0131r [8].<\/p>\n\n\n\n<p class=\"gtfy-82\"><strong>Tart\u0131\u015fma<\/strong><\/p>\n\n\n\n<p class=\"gtfy-85\">Fibromiyalji tedavisinde tek y\u00f6nl\u00fc yakla\u015f\u0131mlar yetersiz kalmakta; bu nedenle multidisipliner, bireyselle\u015ftirilmi\u015f tedavi stratejilerine ihtiya\u00e7 duyulmaktad\u0131r. Tonmya\u2019n\u0131n FDA onay\u0131, farmakolojik tedavi alan\u0131nda uzun s\u00fcredir s\u00fcregelen durgunlu\u011fu k\u0131rmakla birlikte, t\u00fcm hasta gruplar\u0131 i\u00e7in tek ba\u015f\u0131na yeterli olmayabilir.<\/p>\n\n\n\n<p class=\"gtfy-88\">Dijital terapiler, merkezi sinir sistemi hedefli n\u00f6romod\u00fclasyon y\u00f6ntemleri ve mikrobiyota temelli m\u00fcdahaleler, bu tabloya yeni katk\u0131lar sunmaktad\u0131r. Ancak bu alanlardaki \u00e7al\u0131\u015fmalar\u0131n \u00e7o\u011fu erken evre d\u00fczeyindedir.<\/p>\n\n\n\n<p class=\"gtfy-91\"><strong>Sonu\u00e7<\/strong><\/p>\n\n\n\n<p class=\"gtfy-94\">2024\u20132025 y\u0131llar\u0131, fibromiyalji y\u00f6netiminde dikkat \u00e7ekici geli\u015fmelerin ya\u015fand\u0131\u011f\u0131 bir d\u00f6nem olmu\u015ftur. Tonmya&#8217;n\u0131n FDA taraf\u0131ndan onaylanmas\u0131 \u00f6nemli bir geli\u015fme olmakla birlikte, tedaviye yan\u0131t\u0131n ki\u015fisel farkl\u0131l\u0131klar g\u00f6sterdi\u011fi bu sendromda&nbsp;<strong>bireyselle\u015ftirilmi\u015f, \u00e7ok bile\u015fenli<\/strong>&nbsp;bir yakla\u015f\u0131m temel \u00f6nemde kalmaya devam etmektedir.<\/p>\n\n\n\n<p class=\"gtfy-97\">Damgalama, tan\u0131 gecikmesi ve sa\u011fl\u0131k hizmetine eri\u015fim sorunlar\u0131 \u00e7\u00f6z\u00fclmedik\u00e7e, tedavideki bilimsel ilerlemelerin klinik pratikteki etkisi s\u0131n\u0131rl\u0131 kalabilir.<\/p>\n\n\n\n<p class=\"gtfy-100\"><strong>Kaynaklar<\/strong><\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list gtfy-111\">\n<li class=\"gtfy-103 gutenify-list-item\">Clauw DJ. Fibromyalgia: A clinical review. JAMA. 2014;311(15):1547\u201355.<\/li>\n\n\n\n<li class=\"gtfy-104 gutenify-list-item\">Hujjat SFZ, Zahra SH, Abbas T, Kalam H. Tonmya: First FDA-approved therapy for fibromyalgia in 15+ years. Ann Med Surg. 2025;87(12):7868-7869. DOI:10.1097\/MS9.0000000000004010<\/li>\n\n\n\n<li class=\"gtfy-105 gutenify-list-item\">Arnold LM et al. The efficacy of cyclobenzaprine in fibromyalgia. J Clin Rheumatol. 2015;21(3):125\u201330.<\/li>\n\n\n\n<li class=\"gtfy-106 gutenify-list-item\">RELIEF Trial [NCT02634359] \u2013 ClinicalTrials.gov<\/li>\n\n\n\n<li class=\"gtfy-107 gutenify-list-item\">FLEX Long-Term Safety Study. Data on file, Tonix Pharmaceuticals, 2025.<\/li>\n\n\n\n<li class=\"gtfy-108 gutenify-list-item\">PROSPER-FM Trial. The Lancet. 2024. DOI:10.1016\/s0140-6736(24)00909-7<\/li>\n\n\n\n<li class=\"gtfy-109 gutenify-list-item\">Nitsche MA, Paulus W. Transcranial direct current stimulation\u2013update 2019. Brain Stimul. 2019;12(2):489\u2013511.<\/li>\n\n\n\n<li class=\"gtfy-110 gutenify-list-item\">Zhang Y et al. Gut microbiota and metabolite links to fibromyalgia. Nat Metab. 2025;7:112\u2013121.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Fibromiyalji Tedavisinde Yeni Ufuklar: Tonmya\u2019n\u0131n FDA Onay\u0131 ve G\u00fcncel Tedavi Geli\u015fmeleri (2024\u20132025) \u00d6zet Ama\u00e7:&nbsp;Bu derleme, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2278,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_joinchat":[],"footnotes":""},"categories":[],"tags":[],"class_list":["post-2277","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/posts\/2277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/comments?post=2277"}],"version-history":[{"count":0,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/posts\/2277\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/media\/2278"}],"wp:attachment":[{"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/media?parent=2277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/categories?post=2277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/demetdemircioglu.com\/en\/wp-json\/wp\/v2\/tags?post=2277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}